Ask AI
ProCE Banner Activity

CE / CME

From Recurrence to Prevention: Evolving Strategies in Cutaneous Squamous Cell Carcinoma

Clinical Thought

Learn more about how the management of high-risk cutaneous squamous cell carcinoma is evolving toward earlier, proactive intervention with neoadjuvant immunotherapy to prevent recurrence and improve patient outcomes based on key clinical evidence.

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Pharmacists: 0.25 contact hour (0.025 CEUs)

Physicians: maximum of 0.25 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.25 Nursing contact hour

Released: December 31, 2025

Expiration: June 30, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc

Target Audience

This activity is intended for dermatologists, medical oncologists, radiation oncologists, pharmacists, physician associates, advanced practice providers, nurses, and other healthcare professionals who care for patients with cutaneous squamous cell carcinoma.

Program Learning Goal

This activity aims to improve learners’ knowledge and competence to optimally integrate research advances in cSCC care into clinical practice.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Refine evidence-based patient selection criteria for ICI treatment in cSCC, emphasizing clinical risk factors over PD-L1 expression

  • Proactively monitor patients receiving ICI therapy to promptly identify and manage immunotherapy-associated toxicities

  • Implement evidence-based, patient-centered treatment plans for advanced cSCC populations by integrating novel therapeutic strategies such as radiation-immunotherapy sequencing and intralesional therapies

Disclosure

Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

David M. Miller, MD, PhD, FAAD: consultant/advisor/speaker: Almirall, Bristol Myers Squibb, Checkpoint, EMD Serono, Merck, Regeneron, Sanofi Genzyme, Sun; researcher: Kartos, NeoImmune Tech, Regeneron; stock options: Avstera.

Vishal Anil Patel, MD: consultant/advisor/speaker: Almirall, Regeneron, Replimune, Sun.

The planners and content peer reviewers from Decera Clinical Education do not have any relevant financial relationships to disclose, except Kristi K. Orbaugh, MSN, NP, AOCNP, as noted below: 

Kristi K. Orbaugh, MSN, NP, AOCNP: speaker: AstraZeneca, Bristol Myers Squibb, DSI, Exelixis, Lilly, Pfizer, Sobi, Stemline.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 31, 2025, through June 30, 2026:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 contact hour.

Continuing Pharmacy Education

Clinical Care Options, LLC dba Decera Clinical Education designates this continuing education activity for 0.25 contact hour (0.025 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-25-507-H01-P 

Type of Activity: Knowledge 

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

AAPA CME Accreditation - AAPA

Clinical Care Options, LLC dba Decera Clinical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credit. Approval is valid until June 30, 2026. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation


This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

CME Passport

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit cmepassport.org to create your account.